In pancreatic cancer, BMS-754807, a small-molecule inhibitor of the insulin-like growth factor-1 receptor/insulin receptor, improves gemcitabine responsiveness (Awasthi et al., 2012). Here, INSR is linked to pancreatic neoplasm.